NOVAVAX Completes Enrollment In Phase IIa Study Of Seasonal Influenza Vaccine In Older Adults
Novavax, Inc. (Nasdaq: NVAX) announced it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults)...
(more...)
(more...)